BiotechTube
Home/Pipeline/Intranasal NAC

Intranasal NAC

Mild Traumatic Brain Injury (mTBI/Concussion)

Pre-clinicalActive

Key Facts

Indication
Mild Traumatic Brain Injury (mTBI/Concussion)
Phase
Pre-clinical
Status
Active
Company
Neuronasal, Neuronasal

About Neuronasal

Neuronasal is a private, pre-revenue biotech focused on a patented intranasal delivery platform for brain-targeted therapeutics. Its core technology bypasses the blood-brain barrier to deliver the antioxidant drug N-acetylcysteine (NAC) directly to the brain, with initial applications in concussion (mTBI) and Parkinson's Disease. The company has demonstrated proof-of-concept in a human pilot trial, secured key patents and an NIH STTR grant, and is backed by investors including ATAI Life Sciences.

View full company profile

About Neuronasal

Neuronasal is a private, pre-revenue biotech focused on a patented intranasal delivery platform for brain-targeted therapeutics. Its core technology bypasses the blood-brain barrier to deliver the antioxidant drug N-acetylcysteine (NAC) directly to the brain, with initial applications in concussion (mTBI) and Parkinson's Disease. The company has demonstrated proof-of-concept in a human pilot trial, secured key patents and an NIH STTR grant, and is backed by investors including ATAI Life Sciences.

View full company profile

Therapeutic Areas

NeurologyTraumatology